Factor | n | 3-y LRRFS | 3-y DMFS | 3-y DFS | 3-y OS | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Events(n) | Survival | P* | Events(n) | Survival | P* | Events(n) | Survival | P* | Events(n) | Survival | P* | ||
Age | |||||||||||||
  < 50 | 187 | 8 | 96.0% | 0.127 | 9 | 94.9% | 0.049 | 19 | 89.2% | 0.002 | 14 | 91.6% | 0.008 |
  ≥ 50 | 109 | 9 | 92.8% |  | 12 | 90.9% |  | 26 | 79.9% |  | 20 | 82.8% |  |
Gender | |||||||||||||
 Male | 215 | 10 | 97.1% | 0.207 | 19 | 93.9% | 0.057 | 35 | 88.3% | 0.397 | 27 | 88.0% | 0.347 |
 Female | 81 | 7 | 91.5% |  | 2 | 97.0% |  | 10 | 87.6% |  | 7 | 89.2% |  |
T Stage | |||||||||||||
 T1 | 88 | 2 | 98.9% | 0.034 | 6 | 93.1% | 0.855 | 9 | 88.6% | 0.045 | 7 | 92.0% | 0.321 |
 T2 | 89 | 3 | 96.4% |  | 6 | 94.4% |  | 10 | 89.8% |  | 9 | 93.2% |  |
 T3 | 68 | 8 | 86.2% |  | 4 | 91.9% |  | 13 | 79.8% |  | 10 | 81.3% |  |
 T4 | 51 | 4 | 90.3% |  | 5 | 87.5% |  | 13 | 71.6% |  | 8 | 79.9% |  |
Node category | |||||||||||||
 N- | 43 | 2 | 95.0% | 0.762 | 2 | 94.9% | 0.537 | 4 | 90.1% | 0.287 | 4 | 90.5% | 0.664 |
 N+ | 253 | 15 | 97.2% |  | 19 | 94.8% |  | 41 | 82.9% |  | 30 | 88.0% |  |
N Stage | |||||||||||||
 N0 | 43 | 2 | 95.0% | 0.625 | 2 | 94.9% | 0.451 | 4 | 90.1% | 0.401 | 4 | 90.5% | 0.876 |
 N1 | 102 | 4 | 95.7% |  | 7 | 92.1% |  | 14 | 85.2% |  | 11 | 90.0% |  |
 N2 | 132 | 9 | 95.1% |  | 12 | 91.1% |  | 25 | 84.6% |  | 17 | 87.1% |  |
 N3 | 19 | 2 | 88.8% |  | 0 | 100.0% |  | 2 | 88.8% |  | 2 | 86.1% |  |
UICC Stage | |||||||||||||
 I | 15 | 0 | 100.0% | 0.125 | 0 | 100.0% | 0.273 | 0 | 100.0% | 0.019 | 0 | 100.0% | 0.121 |
 II | 76 | 1 | 98.6% |  | 3 | 96.0% |  | 5 | 93.3% |  | 5 | 96.0% |  |
 III | 134 | 11 | 92.6% |  | 13 | 90.3% |  | 26 | 83.9% |  | 20 | 84.4% |  |
 IV | 71 | 5 | 91.8% |  | 5 | 90.9% |  | 14 | 78.0% |  | 9 | 84.4% |  |
Induction chemotherapy was performed or not in stage III-IVpatients | |||||||||||||
 No | 97 | 8 | 89.8% | 0.608 | 9 | 88.8% | 0.650 | 22 | 74.8% | 0.172 | 18 | 79.9% | 0.058 |
 Yes | 108 | 8 | 91.5% |  | 9 | 91.5% |  | 18 | 82.6% |  | 11 | 88.3% |  |